A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business Overview International Stem Cell Corporation (sometimes referred to herein as “ISCO”, the “Company”, “we”, “us”, or “our”) is a clinical stage biotechnology company focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities and two revenue-generating businesses offering potential for increased future revenue. We currently have no revenue generated from our principal operations in therapeutic and clinical product development through research and development efforts. We have generated revenue from our two commercial businesses, anti-aging and research products, of a total of $9.1 million and $7.8 million for the years ended December 31, 2024 and 2023, respectively. Our products are based on multi-decade experience with human cell culture and a proprietary type of pluripotent stem cells, “human parthenogenetic stem cells” (“hpSCs”).
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 9.4M | 9.1M | 7.8M | 8.2M | 7.2M | 7.1M |
| Net Income | -59K | -209K | -131K | -331K | -899K | -2.7M |
| EPS | $-0.01 | $-0.03 | $-0.02 | $-0.04 | $-0.11 | $-0.36 |
| Free Cash Flow | -139K | -153K | 849K | 331K | -1.3M | -369K |
| ROIC | 8.5% | -1.3% | -12.3% | -3.6% | -38.8% | -53.3% |
| Gross Margin | 57.9% | 58.6% | 59.2% | 60.0% | 59.1% | 61.0% |
| Debt/Equity | 0.00 | -1.73 | -1.65 | -1.47 | -0.64 | -0.57 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 97K | -68K | -663K | -183K | -1.9M | -2.8M |
| Operating Margin | 1.0% | -0.7% | -8.5% | -2.2% | -26.8% | -39.5% |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 8M | 7M | 7M | 8M | 8M | 8M |
International Stem Cell CORP passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 59.6%. At current prices, the estimated annualized return to fair value is -3.8%.
International Stem Cell CORP (ISCO) has a 5-year average return on invested capital (ROIC) of -21.9%. This is below average and may indicate limited pricing power.
International Stem Cell CORP (ISCO) has a market capitalization of $1M. It is classified as a small-cap stock.
International Stem Cell CORP (ISCO) does not currently pay a regular dividend.
International Stem Cell CORP (ISCO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
International Stem Cell CORP (ISCO) reported annual revenue of $9 million in its most recent fiscal year, based on SEC EDGAR filings.
International Stem Cell CORP (ISCO) has a net profit margin of -2.3%. The company is currently unprofitable.
International Stem Cell CORP (ISCO) generated $-153 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
International Stem Cell CORP (ISCO) reported earnings per share (EPS) of $-0.03 in its most recent fiscal year.
International Stem Cell CORP (ISCO) has a 5-year average gross margin of 59.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for International Stem Cell CORP (ISCO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
International Stem Cell CORP (ISCO) has a book value per share of $-0.56, based on its most recent annual SEC filing.
No recent press releases.